

# H<sub>2</sub>S: An Endogenous Gas

MANISH A. PATEL and GAURANG B. SHAH

*For author affiliations, see end of text.*

Received February 13, 2007; Revised May 2, 2007; Accepted July 9, 2007

This paper is available online at <http://ijpt.iums.ac.ir>

## ABSTRACT

Gases, such as NO and CO, play important roles both in normal physiology and in diseases. In recent years, interest has been directed towards other naturally-occurring gases, notably H<sub>2</sub>S, which is produced in body by three enzymes, namely cystathionine beta synthase (CBS), cystathionine gamma lyase (CSE) and 3-Mercaptopyruvate sulfurtransferase (MST), present in mitochondria and/or cytosols where main substrate is L-cysteine. Recent studies have shown that vascular tissues generate measurable amount of H<sub>2</sub>S. NO is considered as inducer for H<sub>2</sub>S. H<sub>2</sub>S has gained importance as a neuromodulator and a vasorelaxant factor and as the first endogenous gaseous ATP dependant K<sup>+</sup> channel opener. It potentiates LTP by enhancing NMDA induced inward current. H<sub>2</sub>S induces vasorelaxation, inhibits insulin secretion and also has a role in inflammation. H<sub>2</sub>S also appear to have a role in neuroendocrine fuction because it plays an important role in control of the hypothalamus-pituitary-adrenal axis, inhibit stimulated release of corticotropin-releasing hormone. H<sub>2</sub>S has been found to be decreased in patient with Alzheimer's disease and higher concentrations are found in patients with Down's syndrome. It has a role in development of hypertension, suggesting its role in CNS and CVS disorders. H<sub>2</sub>S it is well known toxic gas with the smell of rotten eggs, is now proposed as a physiologically important molecule.

**Keywords:** *Hydrogen sulfide, ATP dependant K<sup>+</sup> channel opener, Vasorelaxation*

Significant amount of H<sub>2</sub>S is produced in various tissues. Recent studies have shown that vascular tissues generate measurable amount of H<sub>2</sub>S. High concentration of H<sub>2</sub>S has been observed in brain of rats, humans and cows. The H<sub>2</sub>S concentration in rat serum is about 46 μM [1] and in brain tissue is about 50-160 mM [2]. In this review, the formation of H<sub>2</sub>S along with its effect on body has been discussed, which has been depicted in Figure 1.


## FORMATION OF H<sub>2</sub>S

Several enzymes present in mammalian tissues catalyze the desulfhydration of cysteine. 3-Mercaptopyruvate sulfurtransferase (MST) is produced both in mitochondria and in the cytosol, where as cystathionine gamma lyase (CSE) and cystathionine beta synthase (CBS) are produced only in cytosol. The amount of the enzyme produced in mitochondria and cytosol varies depending on the species and organ.

CSE, a pyridoxal 5-phosphate-dependant enzyme, catalyzes the desulfhydration of cysteine which can be inhibited by D L-propargylglycine. A larger proportion of hydrogen sulfide production takes place in the liver. It catalyzes a β-disulfide elimination reaction that results in the production of pyruvate, NH<sub>4</sub><sup>+</sup> and

thiocysteine. Thiocysteine may react with cysteine or other thiols to form hydrogen sulfide [3]. The enzyme activity is about 10 times higher in the rat liver than in the liver of full-term human infants and over 4 times higher than that in the adult human liver [4]. CSE activity in guinea pig is 5-fold lower in the liver and 18-fold lower in the kidney than those in rats [5]. CSE inhibitors do not suppress the production of H<sub>2</sub>S in brain, but suppress its production in the liver and kidney. H<sub>2</sub>S production in brain seems to be unrelated to CSE.

CBS, a pyridoxal 5-phosphate-dependent enzyme, can synthesize hydrogen sulfide from L-cysteine [3]. CBS is the main enzyme responsible for production of H<sub>2</sub>S in the brain. H<sub>2</sub>S is formed by the substitution of the thiol group of L-cysteine with a variety of thiol compounds to form the corresponding thioether. CBS is continuously produced at an especially-high level in the neural and cardiac systems [6]. CBS activity has been measured in various regions of developing rat brain; the activity gradually increases during development at almost the same rate in each region, until the adult level is reached at 4 weeks [7]. H<sub>2</sub>S production from L-cysteine by brain homogenate is inhibited in the presence of CBS inhibitors, such as hydroxylamine and aminooxyacetate [8]. The activity of CBS is regulated presumably at tran-



**Fig 1.** H<sub>2</sub>S formation and its effect on various conditions in body. CSE:cystathionine gamma lyase, CBS: cystathionine beta synthase, MST:Mercaptopyruvate sulfurtransferase, NMDA: N-methyl-D-aspartate, AC: adenylyl cyclase, cAMP:, cyclic adenosine mono phosphate

scriptional level by glucocorticosteroids and cAMP. S-adenosyl L-methionine (SAM) enhances the affinity of the enzyme CBS by allosteric activation. SAM binds to the regulatory domain of CBS, then a conformational change occurs that frees the catalytic domain and CBS become active. In addition SAM and pyridoxal 5-phosphate, it was recently found that Ca<sup>2+</sup>/calmodulin-mediated pathways are involved in the regulation of CBS activity. In the absence of Ca<sup>2+</sup>/calmodulin, the c-terminal domain may cover the catalytic domain and CBS activity remains at a basal level. When Ca<sup>2+</sup>/calmodulin binds to a specific 19 amino-acid sequence, the catalytic domain is exposed by opening of c-terminal domain. CBS mutant, which is deficient in the 19 amino-acid Ca<sup>2+</sup>/calmodulin binding sequence, is constantly active, even in absence of Ca<sup>2+</sup>/calmodulin [9].

MST activity can be detected in mitochondria and cytosolic fractions of rat liver and kidney. MST, a zinc-dependent enzyme, is predominantly localized in proximal tubular epithelium in the kidney, pericentral hepatocytes in the liver, cardiac cells in the heart and neuroglial cells in the brain [10]. MST activity has been measured in various rat and guinea pig tissues. MST activity is sixty times lower in the guinea pig liver than in the rat liver. In mitochondria, MST can produce H<sub>2</sub>S from 3-mercaptopyruvate. It also transfers its sulfur to sulfide from 3-mercaptopyruvate or transfers its sulfur to sulfite, which then forms thiosulfate. In the cytosol, the thiocysteine formed by CSE can act as an acceptor of the sulfur transferred from 3-mercaptopyruvate by

MST [11]. The higher sulfide production capacity of the liver and kidney is markedly inhibited by propargylglycine, a specific inhibitor of CSE, whereas L-aspartate, an inhibitor of the MST pathway, significantly inhibits sulfide production from L-cysteine in the heart but not in the liver or kidney. Thus, sulfide production is mainly due to CSE rather than MST activity in the whole body [11].

Also, H<sub>2</sub>S is produced by non-enzymatically reduction of elemental sulfur to H<sub>2</sub>S using reducing equivalents obtained from the oxidation of glucose. All essential components of this non-enzymatic pathway are present in vivo, including supply of reducible sulfur [12].

#### H<sub>2</sub>S CATABOLISM

In vivo, H<sub>2</sub>S is metabolized by oxidation in mitochondria or by methylation in cytosol. H<sub>2</sub>S can be scavenged by methemoglobin or metallo- or disulfide-containing molecules such as oxidized glutathione. H<sub>2</sub>S is excreted mainly by the kidney as free or conjugated sulfate. Thiosulfate is an intermediate in sulfide oxidation to sulfate. Two enzymes can act on thiosulfate, namely thiosulfate sulfurtransferase and thiosulfate reductase. One molecule of thiosulfate is formed from two molecules of H<sub>2</sub>S [12].

#### EFFECTS OF H<sub>2</sub>S

##### CARDIOVASCULAR SYSTEM

The presence of H<sub>2</sub>S-producing enzyme and endogenous level of H<sub>2</sub>S in cardiovascular system shows that

it has a role in the functioning of cardiovascular system. CSE expression and activity are found in rat portal vein and thoracic aorta. Expression levels of CSE mRNA varies in different types of vascular tissues, with intensity rank of pulmonary artery > aorta > tail artery > mesenteric artery [12]. The CBS does not have major role in H<sub>2</sub>S production in cardiovascular system.

In both in vivo and in vitro experiments, H<sub>2</sub>S has negative inotropic effect on heart. H<sub>2</sub>S is considered as endogenous vasorelaxant factor and has a role in the maintaining blood pressure. I.V. bolus injection of H<sub>2</sub>S decreases central venous pressure and production of endogenous H<sub>2</sub>S. It is essential factor in the development of spontaneous hypertension [13]. Down-regulation of H<sub>2</sub>S/CSE system is considered as a major factor in the development of spontaneous hypertension and the accompanying structural remodeling of aorta [14]. Exogenous administration of H<sub>2</sub>S may attenuate the process of hypertension. Thus, exogenous H<sub>2</sub>S provides a new way for interfering with the progression of hypertension. The hypotensive effect of H<sub>2</sub>S was mimicked by pinacidil and antagonized by glibenclamide [15]. It has been shown by Weimin and Wang (2001) that vasorelaxant effect of H<sub>2</sub>S is mainly mediated by an interaction of the gas with smooth muscle and partially by functional endothelium [16]. H<sub>2</sub>S-induced relaxation of rat aortic tissues was mainly due to direct interaction of H<sub>2</sub>S and SMCs, based on the failure of denervation of vascular tissues in vitro to alter H<sub>2</sub>S effect and on the observation that H<sub>2</sub>S still significantly relaxed vascular tissues after endothelium removal. A small portion of the H<sub>2</sub>S-induced vasorelaxation was attenuated by removal of the endothelium or the application of L-NAME, an inhibitor of NO synthase, in the presence of the endothelium. This endothelium-dependent effect of H<sub>2</sub>S could be explained by the release of endothelium derived vasorelaxant factors in response to H<sub>2</sub>S stimulation because co-application of apamin and charybdotoxin, which can block the effect of endothelium-derived hyperpolarizing factor (EDHF), to the endothelium-intact rat aortic tissues reduced the vasorelaxant effect of H<sub>2</sub>S. It seems that H<sub>2</sub>S might release EDHF from vascular endothelium. The presence of an intact endothelium might serve as a buffer to retain H<sub>2</sub>S in the blood vessel wall, so that its vasorelaxant effect can be potentiated and prolonged.

Unlike NO and CO, H<sub>2</sub>S relaxed vascular tissues independent of the activation of cGMP pathway, where as vasorelaxation induced by NO was virtually abolished by sGC inhibitor ODQ, but ODQ potentiated vasorelaxant effect of H<sub>2</sub>S. Hypothetically, the interaction between H<sub>2</sub>S and ODQ may have generated vasorelaxant free radicals, which further relaxed vascular tissue [16].

The H<sub>2</sub>S-induced vasorelaxation is dependant on extracellular entry of Ca<sup>2+</sup> ions. By directly-acting on vascular SMCs, H<sub>2</sub>S may reduce the extracellular calcium entry and relax vascular tissues. Both endothelium and vascular smooth muscles may serve as targets for H<sub>2</sub>S. By acting on endothelium, H<sub>2</sub>S may facilitate the release of vasorelaxant factors, including NO and EDHF

[16]. The most significant vascular effect of H<sub>2</sub>S is dependent on K<sup>+</sup>/ATP channels. In vascular SMCs, H<sub>2</sub>S-induced relaxation of the aortic tissues precontracted with phenylephrine was mimicked by K<sup>+</sup>/ATP channel opener, pinacidil, but it was concentration-dependently inhibited by glibenclamide. So, H<sub>2</sub>S is the firstly-identified gaseous K<sup>+</sup>/ATP opener in vascular SMCs [15]. It has direct interaction with K<sup>+</sup>/ATP protein without affecting ATP concentration. The opening of K<sup>+</sup>/ATP channels leads to membrane hyperpolarization, which in turn may close voltage-gated calcium channel, thus reduce extracellular calcium entry. Alternatively, H<sub>2</sub>S may directly inhibit voltage-gated Ca<sup>2+</sup> channels in vascular SMCs [16], a possibility that requires further investigation. Hypotension is associated with haemorrhagic shock partly due to the release of endogenous H<sub>2</sub>S. Since, H<sub>2</sub>S is a vasodilator, it seems likely that overproduction of H<sub>2</sub>S during haemorrhagic shock contributes to the hypotension observed [17]. Thus, inhibition of H<sub>2</sub>S biosynthesis represents a novel approach to the treatment of haemorrhagic shock, because inhibition of cardiac H<sub>2</sub>S biosynthesis might also be expected to improve cardiac output due to negative inotropic effect of H<sub>2</sub>S. It is seen that endogenous vascular H<sub>2</sub>S level is increased in rats with septic shock and endotoxic shock. So, it was suggested that endogenous H<sub>2</sub>S was involved in pathophysiological process during shock [18]. Deficiency of H<sub>2</sub>S may also contribute in pathophysiology of some diseases like atherosclerosis, in some patient with hyperhomocysteinemia, and in whom metabolism of homocysteine to cysteine and H<sub>2</sub>S is compromised by vitamin B<sub>6</sub> deficiency [19].

### CENTRAL NERVOUS SYSTEM

First evidence for physiological role of H<sub>2</sub>S was obtained as early as in 1989. CBS and CSE gradually increased after birth and reached adult level at 2-4 week. In rat brain, activities of CBS and CSE in six different region were detected. The activity of CBS was 30 fold greater than CSE and based on Northern blot analysis, CBS is the major enzyme for H<sub>2</sub>S production in brain [8]. Endogenous sulfide level in rat brain tissue (1.6 µg/g) and in normal human postmortem brain stem (0.7 µg/g) was also reported [12].

NaHS at physiologically relevant concentration induced a concentration-dependant (27-200 µM) hyperpolarization and reduced input resistance of CA1 neurons or dorsal raphe neurons. Changes in K<sup>+</sup> conductance were identified to be the main ionic basis for these effects. Change in K<sup>+</sup> conductance is due to the effect of K<sup>+</sup>/ATP channel, while the effect on calcium-activated K<sup>+</sup> channel and voltage-dependant K<sup>+</sup> channels were not supported. Voltage-dependent and TTX-sensitive Na<sup>+</sup> channels may be targeted by H<sub>2</sub>S in neurons. In cultured neuroblastoma cells, NaHS or taurine alone did not alter Na<sup>+</sup> channel currents. After pretreatment of these cells with NaHS, taurine dramatically inhibited Na<sup>+</sup> channels in a reversible fashion. This effect of NaHS was mimicked by disulfide reducing agents dithiothreitol and βmercaptoethanol. A reduction of disulfide bonds between Na<sup>+</sup> channel subunits by H<sub>2</sub>S was suggested as a

probable mechanism. It was also suggested that certain neuronal effects of H<sub>2</sub>S could be mediated by the alteration in taurine levels, because taurine is an inhibitory neurotransmitter and a short exposure to NaHS resulted in a twofold increase of taurine in brainstem, but concentration used in the study was higher than physiological concentration [12].

H<sub>2</sub>S also appears to have a role in neuroendocrine function because it plays an important role in the control of the hypothalamus-pituitary-adrenal axis. Indeed, increases in H<sub>2</sub>S level in hypothalamus either obtained with H<sub>2</sub>S-enriched media or by addition of the H<sub>2</sub>S precursor S-adenosyl L-methionine are associated with inhibition of stimulated release of corticotrophin-releasing hormone from hypothalamic explants. In vivo experiments in rat under rest and after stress-induced adrenocorticle releasing activation show that S-adenosyl L-methionine significantly reduces the rise in serum corticosterone level which [20]. These results show pathophysiological importance of H<sub>2</sub>S in regulation of neuroendocrine function. NMDA receptors are also target for H<sub>2</sub>S, because LTP is altered in CBS knockout mice [21]. In the presence of weak tetanic stimulation, NaHS facilitates LTP by enhancing NMDA-induced inward current and increased cAMP production [8,22]. It increased cAMP production in primarily cultured rat cerebral and cerebellar neurons or in selected rat brain neuronal and glial cell lines. All these observations confirm that H<sub>2</sub>S have a role in some aspect of synaptic activity. Also, it was found that H<sub>2</sub>S level decreased in patient with Alzheimer's disease. On the other hand, excess of H<sub>2</sub>S may lead to mental retardation in patient with Down's syndrome [21], suggesting role of H<sub>2</sub>S in CNS disease as a neuromodulator in the brain.

#### OTHER EFFECTS

H<sub>2</sub>S also have other physiological and pathophysiological role in inflammation, diabetes and oxidative stress. Bhatia and co-workers showed the effect of H<sub>2</sub>S in inflammatory conditions such as acute pancreatitis. According to their observation, prophylactic and therapeutic use of CSE inhibitor, DL-propargylglycine, significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury. These effects of CSE blockade suggest an important proinflammatory role of H<sub>2</sub>S in regulating the severity of pancreatitis and associated lung injury. This raises the possibility that H<sub>2</sub>S may exert similar activity in other forms of inflammation [23].

H<sub>2</sub>S, as a K<sup>+</sup>/ATP channel opener, may have effect on pancreatic K<sup>+</sup>/ATP channel. H<sub>2</sub>S inhibits insulin secretion from pancreatic cell lines and it is high in insulin resistance condition [24]. According to our experiments, H<sub>2</sub>S inhibits insulin secretion and its in vivo effect was inhibited by glibenclamide; which proves the effect of H<sub>2</sub>S on pancreatic K<sup>+</sup>/ATP channel. Streptozotocin-induced diabetes in rats increase expression of CBS and CSE in liver, so H<sub>2</sub>S level is also high in that diabetic rats, suggesting role of H<sub>2</sub>S in pathophysiology of diabetes [25,26]. H<sub>2</sub>S significantly inhibits peroxynitrate-mediated tyrosine nitration and peroxynitrate-induced

cytotoxicity, intracellular protein nitration and protein oxidation in human neuroblastoma 8H-SY5Y cells [27].

#### INTERACTION of H<sub>2</sub>S WITH OTHER GASOTRANSMITTER

Gasotransmitters may interact with one another. H<sub>2</sub>S, NO and CO facilitate the induction of hippocampal LTP. This effect of H<sub>2</sub>S depends on the activation of NMDA receptor whereas that of NO and CO does not. The NO- and CO-induced vasorelaxations are mainly mediated by the cGMP pathway and activation of large conductance K<sup>+</sup>/Ca<sup>2+</sup> channels in vascular SMCs. Vasorelaxant effects of H<sub>2</sub>S is independent on cGMP and K<sup>+</sup>/Ca<sup>2+</sup> channels as well [16]. Competition for the common hemoglobin sink by one gasotransmitter would potentiate or unmask the biological effect of the other gasotransmitter.

H<sub>2</sub>S production in rat aortic tissues is enhanced by NO donor treatment, probably because NO donor also enhances the expression level of CSE in cultured vascular SMCs. Hosoki et al. observed that the vasorelaxant effect of sodium nitroprusside was enhanced by incubation of rat aortic tissues with 30 μM NaHS. On the other side, pretreating aortic tissues with 60 μM H<sub>2</sub>S inhibited the vasorelaxant effect of sodium nitroprusside. So, it was hypothesized that H<sub>2</sub>S may reduce expression of NOS, decrease sensitivity of cGMP pathway to NO or may modify K<sup>+</sup>/Ca<sup>2+</sup> channels to decrease their sensitivity to NO. Also, NO may increase cellular uptake of cysteine [16]. So, it requires further studies to know the interaction between NO and H<sub>2</sub>S which gives complete picture of regulation of vascular tone.

H<sub>2</sub>S was found to be possibly involved in the pathogenesis of hypoxic pulmonary hypertension (HPH). H<sub>2</sub>S was significantly decreased in the pathogenesis of HPH. However, plasma CO level and the expressions of heme oxygenase (HO-1) protein and HO-1 mRNA were significantly increased. Exogenous supply of H<sub>2</sub>S could alleviate the elevation of pulmonary arterial pressure. At the same time, plasma CO level and the expressions of HO-1 protein and mRNA in pulmonary arteries were significantly increased. Exogenous supply of propargylglycine (PPG), an inhibitor of CSE, decreased the plasma H<sub>2</sub>S content and worsened HPH. At the same time, plasma CO level and the expressions of HO-1 protein and mRNA in pulmonary arteries were decreased. The results showed that H<sub>2</sub>S could play a regulatory role in the pathogenesis of HPH through up-regulating of CO/HO pathway [28].

Hemoglobin may be the common "sink" for CO in forming scarlet carboxyhemoglobin, for NO in forming nitrosyl hemoglobin, and for H<sub>2</sub>S in forming green sulfhemoglobin. If this sink is filled with one gas, the binding of other gases would be affected and their individual availability to act on targeted cells would be altered. After pretreatment of human erythrocytes with CO to saturate the hemoglobin sink, the accumulated amount of endogenous H<sub>2</sub>S was significantly enhanced [12].

## FUTURE PROSPECTIVE

H<sub>2</sub>S may have physiological and pathological role, but still there is long way to go to understand cellular metabolism and function of H<sub>2</sub>S. Deficiency in CBS expression causes hyperhomocystinemia, which leads to various diseases. The pathological role of low level of H<sub>2</sub>S in such diseases has not been explored. At present, the main therapeutic provision is to supply vitamin B<sub>6</sub>, B<sub>12</sub> and folic acids. Hydrogen sulfide, another end-metabolic product of homocysteine, obviously reduces homocysteine-induced cardiovascular injury by scavenging oxidative radicals. Increased endogenous or exogenous supply of taurine, hydrogen sulfide and metallothionein might resist cardiovascular injury induced by hyperhomocysteinemia [29]. H<sub>2</sub>S promotes glutamate-mediated transmission via NMDA receptors, which might also have implications for neurodegenerative diseases in which excessive activation of NMDA receptors is involved. H<sub>2</sub>S level were found to be decreased in patients with Alzheimer's disease; deficiency of SAM might underlie the lack of H<sub>2</sub>S in this condition [21]. In Down's syndrome, elevated CBS expression, low plasma homocysteine, and significantly-increased thiosulfate urinary excretion may be associated with abnormally high H<sub>2</sub>S levels. These observations led to the hypothesis that accumulation of H<sub>2</sub>S in the brain could cause the metabolic intoxication [30]. H<sub>2</sub>S is also considered as endogenous vasorelaxant factor. Increased level of H<sub>2</sub>S is associated with hypotension [16]. So, abnormal production of H<sub>2</sub>S or change in expression of CBS could affect blood pressure. Investigation of molecular interaction between NO and H<sub>2</sub>S provides an integrated regulation of vascular tone. Also, molecular mechanism of interaction between H<sub>2</sub>S and K<sup>+</sup> channel require further investigation. H<sub>2</sub>S has effect on vascular and pancreatic K<sup>+</sup> channel without affecting ATP concentration. It was suggested that H<sub>2</sub>S may interact with membrane and/or cytosol proteins to form reactive and unstable persulfides. These persulfides may take different forms, including protein-SSH, Thiotaaurine, thiocysteine, thiocystine, or mercaptopyruvate. The persulfide-related sulfuration and structural changes of the targeted proteins are recognized mechanism underlying the interaction of H<sub>2</sub>S and K<sup>+</sup>/ATP channel proteins [12]. H<sub>2</sub>S inhibit insulin secretion, but on the other hand H<sub>2</sub>S is high in insulin resistance condition because of over expression of CBS and CSE. [24, 26] The role of H<sub>2</sub>S in both type I and II diabetes needs to be investigated.

## REFERENCES

1. Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H<sub>2</sub>S as a novel endogenous gaseous KATP channel opener. *EMBO J* 2001; 20: 6008-16.
2. Hosoki R, Matsuki N, Kimura H. The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. *Biochem Biophys Res Commun.* 1997; 237: 527-31.
3. Stipanuk MH, Beck PW. Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat. *Biochem J* 1982; 206: 267-70.
4. Zlotkin SH, Anderson GH. The development of cystathionase activity during the first year of life. *Pediatr Res* 1982; 16: 65-8.
5. Wrobel M, Ubuka T, Yao WB, Abe T. L-cysteine metabolism in guinea pig and rat tissues. *Comp Biochem Physiol* 1997; 116B: 223-6.
6. Quere I, Paul V, Rouillac C, et al. Spatial and temporal expression of the cystathionine beta-synthase gene during early human development. *Biochem Biophys Res Commun.* 1999; 254: 127-37.
7. Awata S, Nakayama K, Suzuki I, Sugahara K, Kodama H. Changes in cystathionine gamma-lyase in various regions of rat brain during development. *Biochem Mol Biol Int* 1995; 35: 1331-8.
8. Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. *J Neurosci* 1996; 16: 1066-71.
9. Xulin C, Kwang H, Warren D. Production of the Neuromodulator H<sub>2</sub>S by Cystathionine β-Synthase via the Condensation of Cysteine and Homocysteine. *J Biol Chem* 2004 10; 279: 52082-6.
10. Nagahara N, Ito T, Kitamura H, Nishino T. Tissue and subcellular distribution of mercaptopyruvate sulfurtransferase in the rat: confocal laser fluorescence and immunoelectron microscopic studies combined with biochemical analysis. *Histochem Cell Biol.* 1998; 110: 243-50.
11. Kamoun P. Endogenous production of hydrogen sulfide in mammals. *Amino Acids* 2004; 26: 243-54.
12. Wang R. Two's company, three's crowd: can H<sub>2</sub>S be the third endogenous gaseous transmitter? *SABES J* 2002; 16: 1792-8.
13. Du J, Yan H, Tang C. Endogenous H<sub>2</sub>S is involved in the development of spontaneous hypertension. *Beijing Da Xue Xue Bao.* 2003; 35: 102.
14. Yan H, Du JB, Tang CS. Changes of endogenous hydrogen sulfide (H<sub>2</sub>S) in hypertensive rats. *Zhonghua Er Ke Za Zhi* 2004; 42: 172-5.
15. Weimin Z, Jing Z, Yanjie L, Wang R. The vasorelaxant effect of H<sub>2</sub>S as a novel endogenous gaseous KATP channel opener. *EMBO J* 2001; 20: 6008-16.
16. Weimin Z, Wang R. H<sub>2</sub>S-induced vasorelaxation and underlying cellular and molecular mechanisms. *Am J Physiol Heart Circ Physiol* 2002; 283 :H474-H480.
17. Mok YY, Atan MS, Yoke PC, et al. Role of hydrogen sulphide in haemorrhagic shock in the rat: protective effect of inhibitors of hydrogen sulphide biosynthesis. *Br J Pharmacol.* 2004; 143: 881-9.
18. Hui Y, Du J, Tang C, Bin G, Jiang H. Changes in arterial hydrogen sulfide (H<sub>2</sub>S) content during septic shock and endotoxin shock in rats. *J Infect.* 2003; 47: 155-60.
19. Beltowski J. Hydrogen sulfide as a biologically active mediator in the cardiovascular system. *Postepy Hig Med Dosw.* 2004; 58: 285-91.
20. Dello Russo C, Tringali G, Ragazzoni E, et al. Evidence That hydrogen sulphide can modulate hypothalamo-pituitary-adrenal axis function: in vitro and in vivo studies in the rat. *J Neuroendocrinol* 2000; 12: 225-33.
21. Philip M, Madhav B, Shabbir M. Hydrogen sulfide: from the smell of the past to the mediator of the future? *Trend Pharmacol Sci* 2003; 24: 609-11.
22. Kimura H. Hydrogen sulfide induces cyclic AMP and modulates the NMDA receptor. *Biochem Biophys Res Commun* 2000; 267:129-133.
23. Bhatia M, Wong FL, Fu D, Lau HY, Moochhala SM, Moore PK. Role of hydrogen sulfide in acute pancreatitis and associated lung injury. *FASEB J.* 2005; 19: 623-5.
24. Jia X, Yang W, Jakic Z, Wang R, Wu L. The role of hydrogen sulfide in insulin resistance. *Canadian cardiovascular congress,* 2004.

25. Hargrove JL, Trotter JF, Ashline HC, Krishnamurti PV. Experimental diabetes increases the formation of sulfane by transsulfuration and inactivation of tyrosine aminotransferase in cytosols from rat liver. *Metabolism* 1989; 38: 666-72.
26. Muhammed Y, Benny T, Kwong H, Hsu A, Matthew W, Madhav B, Philip M. Streptozotocin-induced diabetes in the rat is associated with enhanced tissue hydrogen sulfide biosynthesis. *Biochem Biophys Res Commun* 2005; 333: 1146-52.
27. Whiteman M, Armstrong JS, Chu SH, et al. The novel neuro-modulator hydrogen sulfide: an endogenous peroxynitrite scavenger? *J Neurochem.* 2004; 90: 765-8.
28. Qingyou Z, Junbao D, Weijin Z, Hui Y, Chaoshu T, Chunyu Z. Impact of hydrogen sulfide on carbon monoxide/heme oxygenase pathway in the pathogenesis of hypoxic pulmonary hypertension. *Biochem Biophys Res Commun* 2004; 317:30-7.
29. Geng B, Yang J, Qi Y, et al. H<sub>2</sub>S generated by heart in rat and its effect on cardiac function. *Biochem Biophys Res Commun* 2004; 313: 362-8.
30. Kamoun P. Mental retardation in Down syndrome: a hydrogen sulfide hypothesis. *Med Hypothesis* 2001; 57: 389-92.

#### CURRENT AUTHOR ADDRESSES

MANISH A. PATEL, Department of pharmacology, vidyabharati trust college of pharmacy, Bardoli-mota road. Umrakh, Ta.Bardoli, Di. Surat, GujaratIndia. E-mail: manishpatelrx@rediffmail.com (Corresponding author)

GAURANG B. SHAH, Department of pharmacology, K.B. Institute of Pharmaceutical Education and Research, Sector 23, GH-6, Gandhinagar, India.